18 F-DCFPyL PET/CT guidelines.

Autor: Gutiérrez Cardo AL; Servicio de Medicina Nuclear, Hospital Regional de Málaga, Málaga, Spain., Vallejo Casas JA; Servicio de Medicina Nuclear, Hospital Universitario Reina Sofía, Córdoba, Spain., García Garzón JR; Servicio de Medicina Nuclear, Cetir-Ascires, Barcelona, Spain., Tirado Hospital JL; Servicio de Medicina Nuclear, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Medina López R; Unidad de Nefrourología, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Freire Macías JM; Servicio de Medicina Nuclear, Hospital Universitario Puerta del Mar, Cádiz, Spain., Rodríguez Fernández A; Servicio de Medicina Nuclear, Hospital Universitario Virgen de las Nieves, Granada, Spain. Electronic address: antonio.rodriguez.fernandez.sspa@juntadeandalucia.es.
Jazyk: angličtina
Zdroj: Revista espanola de medicina nuclear e imagen molecular [Rev Esp Med Nucl Imagen Mol (Engl Ed)] 2023 May-Jun; Vol. 42 (3), pp. 203-208. Date of Electronic Publication: 2023 Mar 05.
DOI: 10.1016/j.remnie.2023.02.009
Abstrakt: The objective of this guide is to provide to nuclear medicine physicians a tool based on scientific evidence and prepared by consensus of experts, to perform the 18 F-DCFPyL PET/CT procedure with safely and efficiently for patients with prostate cancer who present PSMA overexpression. For them, some recommendations will be established for 18 F-DCFPyL PET/CT examination: reconstruction parameters, presentation of the images and their interpretation. The possible false positives of the procedure will be analysed, how to interpret them and how to avoid them. Finally, all exploration should lead to the preparation of a report that answers the clinician's question. For this, it is recommended to prepare a structured report that includes the PROMISE criteria as well as the classification of the findings according to PSMA-RADS parameters.
(Copyright © 2023 Sociedad Española de Medicina Nuclear e Imagen Molecular. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE